Additionally, as already mentioned, both GzmB from killer cytotoxic lymphocytes18 or combined BRAF inhibitor and MEK inhibitor treatment39 can trigger GSDME‐dependent pyroptosis in cancer cells downstream of caspase‐3 activation (Figure 2b). Here, GSDME is linked to cancer.